Posterior reversible encephalopathy syndrome du... [J Clin Oncol. 2012] - PubMed

loading

Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. [Ann Hematol. 2010]
Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
Hosoi M, Yamamoto G, Imai Y, Kurokawa M. Ann Hematol. 2010 Feb; 89(2):207-8. Epub 2009 Jul 7.
Ipilimumab approved for metastatic melanoma. [Am J Health Syst Pharm. 2011]
Ipilimumab approved for metastatic melanoma.
Traynor K. Am J Health Syst Pharm. 2011 May 1; 68(9):768.
Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab. [Clin Experiment Ophthalmol. 2008]
Reversible posterior leukoencephalopathy syndrome and intravenous bevacizumab.
Peter S, Hausmann N, Schuster A, Boehm HF. Clin Experiment Ophthalmol. 2008 Jan-Feb; 36(1):94-6.
Review Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. [Clin Cancer Res. 2011]
Review Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma.
Lipson EJ, Drake CG. Clin Cancer Res. 2011 Nov 15; 17(22):6958-62. Epub 2011 Sep 7.
Review Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. [Semin Oncol. 2010]
Review Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R. Semin Oncol. 2010 Oct; 37(5):533-46.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Posterior reversible encephalopathy syndrome during ipilimumab therapy for malig...
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma.
J Clin Oncol. 2012 Feb 20 ;30(6):e76-8. Epub 2011 Dec 27 .

PubMed
Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in ...
Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.
J Clin Oncol. 2012 Feb 1 ;30(4):347-50. Epub 2011 Dec 27 .

PubMed
Effect of early palliative care on chemotherapy use and end-of-life care in pati...
Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
J Clin Oncol. 2012 Feb 1 ;30(4):394-400. Epub 2011 Dec 27 .

PubMed
Phase II, open-label, randomized, multicenter study comparing the efficacy and s...
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
J Clin Oncol. 2012 Feb 1 ;30(4):372-9. Epub 2011 Dec 27 .

PubMed
Endocrine basis for growth-promoting therapy.
Endocrine basis for growth-promoting therapy.
Acta Paediatr Scand Suppl. 1990 ;367:11-3.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed